Evotec and Apeiron Biologics enter pain collaboration
Evotec and Apeiron Biologics are joining forces to identify small molecule modulators of DREAM (Downstream Regulatory Element Antagonistic Modulator), a novel target involved in perception of various pain mechanisms.
Under the agreement, Evotec will offer its expertise in cellular assay development, and plans to quickly move into hit identification.
"Combining our two companies' skills is an excellent way to move forward with this innovative and promising project,” commented Dr Hans Loibner, CEO at Apeiron Biologics. “We have worked with Evotec in the past and continue to be impressed by the quality of the work performed there," he added.
Dr Werner Lanthaler, CEO at Evotec, went on to say, "Apeiron is certainly one of the most exciting young biotech companies in Europe. We are happy that through the optimal use of R&D outsourcing Evotec can add value here."
Financial details of the collaboration remain undisclosed.